🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Early on-treatment CRP kinetics is a promising low-cost and easy-to-implement biomarker to optimize therapy monitoring in patients with mRCC treated with immunotherapy. Thanks to the collaborators! Michael Hölzel IEO_HölzelLab @Zeuschner_P chariskalogirou

CRP flare 🔥! Longitudinal CRP kinetics predicts response to immunotherapy in NSCLC as early as 4 weeks after therapy start. Simple on-treatment biomarker to optimize monitoring. Chance for early therapy adjustments. Thanks to all collaborators! @docbald IEO_HölzelLab Rheinische Friedrich-Wilhelms-Universität Bonn

C-reactive protein flare predicts response to immunotherapy in UC🔥Thus, early longitudinal CRP kinetics has predictive value across entities (also proven for RCC + NSCLC)! Thanks to all collaborators! ejcancer.com/article/S0959-… Markus Eckstein IEO_HölzelLab IEO_Bonn Rheinische Friedrich-Wilhelms-Universität Bonn

Important work led by my colleagues Jonas Saal and Niklas Klümper published in Annals of Oncology. mGPS has the potential to significantly refine and simplify the therapy algorithm in mRCC! Congratulations! IEO_HölzelLab Uniklinik Bonn

The IMDC score is used for risk stratification in the 1st line treatment of mRCC. The mGPS, based on baseline CRP + albumin levels, was tested on data from the IMmotion151 ph3 clinical trial. Results 👇 annalsofoncology.org/article/S0923-… Jonas Saal Niklas Klümper IEO_Bonn Rheinische Friedrich-Wilhelms-Universität Bonn

Happy to share our work: Integrating On-Treatment Modified Glasgow Prognostic Score and Imaging to Predict Response and Outcomes in Metastatic Renal Cell Carcinoma JAMA Oncology. See our tweetorial and the terrific editorial by Georges Gebrael Gliceida Galarza, MD Neeraj Agarwal, MD, FASCO UroToday.com 1/7

A new research in JAMA Network shows that longitudinal measurement of systemic inflammatory response (through mGPS) in patients with mRCC provides valuable prognostic information and could integrate radiological staging in therapy monitoring jamanetwork.com/journals/jamao…

Prognostication & monitoring are key to further develop therapies for mRCC! Excited to discuss our insights European Urology on the role of IMDC and inflammatory biomarkers like mGPS (CRP + albumin) in current 1st line mRCC treatment Viktor Grünwald UroToday.com authors.elsevier.com/a/1hhGd14kplvA…

Guru P. Sonpavde, MD Great news! But how will EV compete with the other ADC (Trop2, Her2) and Erda. Predictive biomarkers urgently needed for mUC. We and others argue for incorporation of NECTIN-4 expression in future biomarker strategies pubmed.ncbi.nlm.nih.gov/36749325/ David H Aggen, MD PhD Carissa Chu Jonathan Rosenberg MD

Great news for patients with met. UC! But do all patients benefit or what could be the role of predictive biomarkers for EV response like NECTIN4 status? Markus Eckstein Viktor Grünwald UroToday.com OncoAlert Clinical Cancer Research aacrjournals.org/clincancerres/…

Prediction of therapy response based on RECIST criteria only has limitations for the immunotherapy era! Longitudinal assessment of simple inflammatory 🔥blood biomarkers (CRP + albumin integrated into modified Glasgow Prognostic Score/ mGPS) provides complementary information

Transformative results of EV-302 nicely summarized in this NEJM Quick Take video! But how to move forward for mUC now?🤔 Identifying biomarkers of resistance to EV+PEM is key to further improve outcomes for mUC 🔎 The most intuitive biomarker for predicting response/

Happy to share our commentary about EV-302 European Urology European Association of Urology (EAU) - Thanks to Markus Eckstein Boris Hadaschik Viktor Grünwald Identification of patients with low or minimal chances of benefiting from EV/P is crucial, as there are other effective therapies available (eg,